1 – For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Faricimab
f. Ranibizumab – Lucentis
g. Ranibizumab – Ongavia
2 – For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Faricimab
f. Ranibizumab – Lucentis
g. Ranibizumab – Ongavia
3 – How many patients have you treated in the last 12 months with the following drugs?
a. Genotropin
b. Humatrope
c. Norditropin
d. Nutropin
e. Omnitrope
f. Saizen
g. Zomacton
h. Any other Somatropin (please specify)

High-cost drugs in Ophthalmology and Metabolic diseases.10.01.23.docx